Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study

1 Apr 2016The Lancet Haematology

DOI : 10.1016/s2352-3026(15)00247-1

Authors

Céline Berthon, Emmanuel Raffoux, Xavier Thomas, Norbert Vey, Carlos Gomez-Roca, Karen Yee, David Christopher Taussig, Keyvan Rezai, Christophe Roumier, Patrice Herait, Carmen Kahatt, Bruno Quesnel, Mauricette Michallet, Christian Recher, François Lokiec, Claude Preudhomme, Hervé Dombret